Okayama University

Hiroki Kakuta

Hiroyuki Michiue

Shuichi Furuya

Yasuaki Takeuchi

Hideki Matsui

Kenji Sasaki

Arihiko Kanehiro

Kazunori Morohashi

Kenichi Morishita

Naohiro Oda

Toshitaka Oohashi

Nobuaki Miyahara

Kayo Takamatsu

Daisuke Morichika

Atsushi Takano

Utako Fujii

Akihiko Taniguchi

Nobumasa Yakushiji

There is provided a drug for preventing or treating inflammatory bowel disease, comprising as an active ingredient an RXR agonist which is a compound represented by Formula (1). In Formula (1), it is preferred that: Ris an alkyl group; Ris an alkyl group; W is NR, and Ris an alkyl group; Xis CH; Yis N; Xand Yare CH; and Z is a carboxyl group. Thus, a drug capable of strongly preventing or treating inflammatory bowel disease while suppressing the onset of side effects is provided. 

Drug for preventing or treating inflammatory bowel disease

A method for treating an inflammatory respiratory disease, comprising administering an effective amount of an RXR agonist represented by formula (1) or (2) as an active ingredient. wherein D, R, R, X, Y, Z, R, R, X, Y, X, Yand Zare defined.

Medicinal composition for preventing or treating inflammatory respiratory disease

The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.

BSH complex for boron neutron capture therapy

There is provided a pharmaceutical composition for treatment or prevention of a neurodegenerative disease, comprising an RXR agonist as an active ingredient, which is a compound represented by formula (1) or (2). The pharmaceutical composition is effective in treatment or prevention of neurodegenerative diseases such as dementia, Parkinson's disease and multiple sclerosis with reducing side effects such as enlargement of the liver and elevation of blood triglyceride level. In these formulas, A represents CMe, N-methyl, N-ethyl or N-isopropyl; X represents N, CH or C&#x2014;CF; Y and Z represent N or CH; Rrepresents methyl, hydroxy, methoxy or ethoxy; Rrepresents H, methyl or ethyl; B represents NRor CHR; Rrepresents alkyl; and Rrepresents H, halogen, alkyl, alkenyl, aryl, alkynyl, alkoxy or acyl. 

Pharmaceutical composition for treatment or prevention of neurodegenerative diseases

There is provided a lysine oligomer derivative, wherein an &#x3b5;-amino group and a carboxyl group of lysines are linked via a peptide bond, and a group capable of generating or absorbing electromagnetic wave is bonded to a C-terminal carboxyl group, an N-terminal amino group and/or an &#x3b1;-amino group. This lysine oligomer derivative has the characteristic of specifically accumulating in the cartilage matrix and can generate or absorb an electromagnetic wave, and is, therefore, useful as a cartilage tissue marker.

Lysine oligomer derivative and cartilage tissue marker made thereof

Disclosed is a compound represented by the general formula shown below, which can bind to a retinoid X receptor (RXR), which is one of nuclear receptors, and exhibit an agonistic or antagonistic action. [Wherein, Ris selected from the group consisting of an alkyl group, an alkenyl group, an alkynyl group and an aryl group. Ris selected from the group consisting of an alkoxy group, an alkyl group, an alkenyl group, an alkynyl group and an aryl group. W is NRor CR; and Ris selected from a hydrogen, an alkyl group, an alkenyl group, an alkynyl group and an aryl group. Xand Yare selected from CH or N. Xand Yare selected from CH, CRor N. Ris selected from an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogen, a nitro group and an amino group. Z is selected from a carboxylic acid, a carboxylate ester or a hydroxamic acid, which is bound directly or via an alkyl group, an alkenyl group or an alkynyl group.] 

Rexinoid compound having alkoxy group

Growing community of inventors

Okayama, Japan

Hiroki Kakuta